{"entity":{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","aka":[],"tldr":"MBrace Therapeutics is a United States-based biotechnology company running 2 late-stage cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer and colorectal cancer.","summary":"MBrace Therapeutics, based in San Diego, CA, the United States, is a biotechnology company. MBrace Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, using a proprietary in vivo target-discovery platform called SPARTA. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer, colorectal cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07145255 (Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.mbracetrx.com"},{"label":"ClinicalTrials.gov: trials led by MBrace Therapeutics","url":"https://clinicaltrials.gov/search?lead=MBrace%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate","breast-hr-positive","colorectal","nsclc","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07145255","nct06014658"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://www.mbracetrx.com","stage":"startup","investors":[],"funding":[]},"route":"/companies/mbrace-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"trial":[{"id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/"},{"id":"nct06014658","kind":"trial","name":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","route":"/trials/nct06014658/"}]}}